Skip to main content

Advertisement

SpringerLink
Log in

The Effects of Supplement Therapy on HCV-Related HCC: a Case Report of a Patient Who Had Undergone TACE for Six Times

  • Case Report
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Goodarzi E, Ghorat F, Jarrahi AM, Adineh HA, Sohrabivafa M, Khazaei Z. Global incidence and mortality of liver cancers and its relationship with the Human Development Index (HDI): an ecology study in 2018. World Cancer Res J. 2019;6:e1255. https://doi.org/10.32113/wcrj_20194_1255.

    Article  Google Scholar 

  2. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142(6):1264–1273.e1. https://doi.org/10.1053/j.gastro.2011.12.061.

    Article  PubMed  Google Scholar 

  3. The Global Cancer Observatory. Myanmar fact sheets. International Agency for Research on Cancer, World Health Organization. 2019. https://gco.iarc.fr/today/data/factsheets/populations/104-myanmar-fact-sheets.pdf. Accessed 10 August 2020.

  4. Global Burden of Disease Liver Cancer Collaboration, Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015. JAMA Oncol. 2017;3(12):1683–91. https://doi.org/10.1001/jamaoncol.2017.3055.

    Article  PubMed Central  Google Scholar 

  5. Sangiovanni A, Prati GM, Fasani P, Ronchi G, Romeo R, Manini M, et al. The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. Hepatol. 2006;43(6):1303–10. https://doi.org/10.1002/hep.21176.

    Article  Google Scholar 

  6. Cicalese L. Hepatocellular carcinoma (HCC): practice essentials, anatomy, pathophysiology. 2020. https://emedicine.medscape.com/article/197319-overview . Accessed 26 August 2020.

  7. Nagasue N, Uchida M, Makino Y, Takemoto Y, Yamanoi A, Hayashi T, et al. Incidence and factors associated with intrahepatic recurrence following resection of hepatocellular carcinoma. Gastroenterology. 1993;105(2):488–94. https://doi.org/10.1016/0016-5085(93)90724-Q.

    Article  CAS  PubMed  Google Scholar 

  8. Llovet J, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatol. 2003;37(2):429–42. https://doi.org/10.1053/jhep.2003.50047.

    Article  CAS  Google Scholar 

  9. Lencioni R, Crocetti L. Local-regional treatment of hepatocellular carcinoma. Radiology. 2012;262(1):43–58. https://doi.org/10.1148/radiol.11110144.

    Article  PubMed  Google Scholar 

  10. Lencioni R, de Baere T, Soulen MC, Rilling WS, Geschwind J-FH. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data. Hepatol. 2016;64(1):106–16. https://doi.org/10.1002/hep.28453.

    Article  CAS  Google Scholar 

  11. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med. 1995;332(19):1256–61. https://doi.org/10.1056/nejm199505113321903.

    Article  Google Scholar 

  12. Cheng A-L, Kang Y-K, Chen Z, Tsao C-J, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34. https://doi.org/10.1016/s1470-2045(08)70285-7.

    Article  CAS  PubMed  Google Scholar 

  13. Galle PR, Forner A, Llovet JM, Mazzaferro V, Piscaglia F, Raoul J-L, et al. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236. https://doi.org/10.1016/j.jhep.2018.03.019.

    Article  Google Scholar 

  14. Mathew S, Faheem M, Suhail M, Fatima K, Archunan G, Begum N, et al. Updates on traditional medicinal plants for hepatocellular carcinoma. Pharmacogn J. 2016;8(3):203–14.

    Article  CAS  Google Scholar 

  15. Kawai S, Okamura J, Ogawa M, Ohashi Y, Tani M, Inoue J, et al. Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma ? A comparison of lipiodol-transcatheter arterial embolization with and without Adriamycin (first cooperative study). Cancer Chemother Pharmacol. 1992;31(S1):S1–6. https://doi.org/10.1007/bf00687096.

    Article  PubMed  Google Scholar 

  16. Oliveri RS, Wetterslev J, Gluud C. Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev. 2011;3:CD004787. https://doi.org/10.1002/14651858.cd004787.pub2.

    Article  Google Scholar 

  17. Kudo M, Ueshima K, Ikeda M, Torimura T, Tanabe N, Aikata H, et al. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut. 2020;69(8):1492–501. https://doi.org/10.1136/gutjnl-2019-318934.

    Article  PubMed  Google Scholar 

  18. Mastron JK, Siveen KS, Sethi G, Bishayee A. Silymarin and hepatocellular carcinoma: a systematic, comprehensive, and critical review. Anti-Cancer Drug. 2015;26(5):475–86. https://doi.org/10.1097/cad.0000000000000211.

    Article  CAS  Google Scholar 

  19. Yurtcu E, Iseri OD, Sahin FI. Effects of silymarin and silymarin-doxorubicin applications on telomerase activity of human hepatocellular carcinoma cell line HepG2. J BUON. 2015;20(2):555–61.

    PubMed  Google Scholar 

  20. Ramakrishnan G, Lo Muzio L, Elinos-Báez CM, Jagan S, Augustine TA, Kamaraj S, et al. Silymarin inhibited proliferation and induced apoptosis in hepatic cancer cells. Cell Prolif. 2009;42(2):229–40. https://doi.org/10.1111/j.1365-2184.2008.00581.x.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Varghese L. Silibinin efficacy against human hepatocellular carcinoma. Clin Cancer Res. 2005;11(23):8441–8. https://doi.org/10.1158/1078-0432.ccr-05-1646.

    Article  CAS  PubMed  Google Scholar 

  22. Zhang S, Yang Y, Liang Z, Duan W, Yang J, Yan J, et al. Silybin-mediated inhibition of notch signaling exerts antitumor activity in human hepatocellular carcinoma cells. PLoS One. 2013;8(12):e83699. https://doi.org/10.1371/journal.pone.0083699.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Zappavigna S, Vanacore D, Lama S, Potenza N, Russo A, Ferranti P, et al. Silybin-induced apoptosis occurs in parallel to the increase of ceramides synthesis and miRNAs secretion in human hepatocarcinoma cells. Int J Mol Sci. 2019;20(9):2190. https://doi.org/10.3390/ijms20092190.

    Article  CAS  PubMed Central  Google Scholar 

  24. Ramakrishnan G, Raghavendran HRB, Vinodhkumar R, Devaki T. Suppression of N-nitrosodiethylamine induced hepatocarcinogenesis by silymarin in rats. Chem Biol Interact. 2006;161(2):104–14. https://doi.org/10.1016/j.cbi.2006.03.007.

    Article  CAS  PubMed  Google Scholar 

  25. Gopalakrishnan R, Sundaram J, Sattu K, Pandi A, Thiruvengadam D. Dietary supplementation of silymarin is associated with decreased cell proliferation, increased apoptosis, and activation of detoxification system in hepatocellular carcinoma. Mol Cell Biochem. 2013;377(1–2):163–76. https://doi.org/10.1007/s11010-013-1582-1.

    Article  CAS  PubMed  Google Scholar 

  26. Sangsefidi ZS, Yaghoubi F, Hajiahmadi S, Hosseinzadeh M. The effect of coenzyme Q10 supplementation on oxidative stress: a systematic review and meta-analysis of randomized controlled clinical trials. Food Sci Nutr. 2020;8(4):1766–76. https://doi.org/10.1002/fsn3.1492.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Fouad AA, Al-Mulhim AS, Jresat I. Therapeutic effect of coenzyme Q10 against experimentally-induced hepatocellular carcinoma in rats. Environ Toxicol Pharmacol. 2013;35(1):100–8. https://doi.org/10.1016/j.etap.2012.11.016.

    Article  CAS  PubMed  Google Scholar 

  28. Liu H-T, Huang Y-C, Cheng S-B, Huang Y-T, Lin P-T. Effects of coenzyme Q10 supplementation on antioxidant capacity and inflammation in hepatocellular carcinoma patients after surgery: a randomized, placebo-controlled trial. Nutr J. 2015;15(1):85. https://doi.org/10.1186/s12937-016-0205-6.

    Article  CAS  Google Scholar 

  29. Ko J-H, Sethi G, Um J-Y, Shanmugam MK, Arfuso F, Kumar AP, et al. The role of resveratrol in cancer therapy. Int J Mol Sci. 2017;18(12):2589. https://doi.org/10.3390/ijms18122589.

    Article  CAS  PubMed Central  Google Scholar 

  30. Bishayee A, Politis T, Darvesh AS. Resveratrol in the chemoprevention and treatment of hepatocellular carcinoma. Cancer Treat Rev. 2010;36(1):43–53. https://doi.org/10.1016/j.ctrv.2009.10.002.

    Article  CAS  PubMed  Google Scholar 

  31. Gao F, Deng G, Liu W, Zhou K, Li M. Resveratrol suppresses human hepatocellular carcinoma via targeting HGF-c-Met signaling pathway. Oncol Rep. 2017;37(2):1203–11. https://doi.org/10.3892/or.2017.5347.

    Article  CAS  PubMed  Google Scholar 

  32. Yeh C-B, Hsieh M-J, Lin C-W, Chiou H-L, Lin P-Y, Chen T-Y, et al. The antimetastatic effects of resveratrol on hepatocellular carcinoma through the downregulation of a metastasis-associated protease by SP-1 modulation. PLoS One. 2013;8(2):e56661. https://doi.org/10.1371/journal.pone.0174494.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Zhang Y, Duan W, Owusu L, Wu D, Xin Y. Epigallocatechin-3-gallate induces the apoptosis of hepatocellular carcinoma LM6 cells but not non-cancerous liver cells. Int J Mol Med. 2015;35(1):117–24. https://doi.org/10.3892/ijmm.2014.1988.

    Article  CAS  PubMed  Google Scholar 

  34. Nishikawa T, Nakajima T, Moriguchi M, Jo M, Sekoguchi S, Ishii M, et al. A green tea polyphenol, epigalocatechin-3-gallate, induces apoptosis of human hepatocellular carcinoma, possibly through inhibition of Bcl-2 family proteins. J Hepatol. 2006;44(6):1074–82. https://doi.org/10.1016/j.jhep.2005.11.045.

    Article  CAS  PubMed  Google Scholar 

  35. Zhang Q, Tang X, Lu Q, Zhang Z, Rao J, Le AD. Green tea extract and (−)-epigallocatechin-3-gallate inhibit hypoxia- and serum-induced HIF-1α protein accumulation and VEGF expression in human cervical carcinoma and hepatoma cells. Mol Cancer Ther. 2006;5(5):1227–38. https://doi.org/10.1158/1535-7163.mct-05-0490.

    Article  CAS  PubMed  Google Scholar 

  36. Kaufmann R, Henklein P, Henklein P, Settmacher U. Green tea polyphenol epigallocatechin-3-gallate inhibits thrombin-induced hepatocellular carcinoma cell invasion and p42/p44-MAPKinase activation. Oncol Rep. 2009;21(5):1261–7. https://doi.org/10.3892/or_00000349.

    Article  CAS  PubMed  Google Scholar 

  37. Zapf MAC, Kothari AN, Weber CE, Arffa ML, Wai PY, Driver J, et al. Green tea component epigallocatechin-3-gallate decreases expression of osteopontin via a decrease in mRNA half-life in cell lines of metastatic hepatocellular carcinoma. Surgery. 2015;158(4):1039–48. https://doi.org/10.1016/j.surg.2015.06.011.

    Article  PubMed  Google Scholar 

  38. Hisaka T, Sakai H, Sato T, Goto Y, Nomura Y, Fukutomi S, et al. Quercetin suppresses proliferation of liver cancer cell lines in vitro. Anticancer Res. 2020;40(8):4695–700. https://doi.org/10.21873/anticanres.14469.

    Article  CAS  PubMed  Google Scholar 

  39. Ji Y, Li L, Ma Y-X, Li W-T, Li L, Zhu H-Z, et al. Quercetin inhibits growth of hepatocellular carcinoma by apoptosis induction in part via autophagy stimulation in mice. J Nutr Biochem. 2019;69:108–19. https://doi.org/10.1016/j.jnutbio.2019.03.018.

    Article  CAS  PubMed  Google Scholar 

  40. Lee RH, Cho JH, Jeon Y-J, Bang W, Cho J-J, Choi N-J, et al. Quercetin induces antiproliferative activity against human hepatocellular carcinoma (HepG2) cells by suppressing specificity protein 1 (Sp1): antiproliferative activity of quercetin involves SP1. Drug Dev Res. 2015;76(1):9–16. https://doi.org/10.1002/ddr.21235.

    Article  CAS  PubMed  Google Scholar 

  41. Wu L, Li J, Liu T, Li S, Feng J, Yu Q, et al. Quercetin shows anti-tumor effect in hepatocellular carcinoma LM3 cells by abrogating JAK2/STAT3 signaling pathway. Cancer Med. 2019;8(10):4806–20. https://doi.org/10.1002/cam4.2388.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Yang J, Pi C, Wang G. Inhibition of PI3K/Akt/mTOR pathway by apigenin induces apoptosis and autophagy in hepatocellular carcinoma cells. Biomed Pharmacother. 2018;103:699–707. https://doi.org/10.1016/j.biopha.2018.04.072.

    Article  CAS  PubMed  Google Scholar 

  43. Sung B, Chung HY, Kim ND. Role of apigenin in cancer prevention via the induction of apoptosis and autophagy. J Cancer Prev. 2016;21(4):216–26. https://doi.org/10.15430/jcp.2016.21.4.216.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Shankar E, Goel A, Gupta K, Gupta S. Plant flavone apigenin: an emerging anticancer agent. Curr Pharmacol Rep. 2017;3(6):423–46. https://doi.org/10.1007/s40495-017-0113-2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Lwin KM, Lwin MKT. Vitis species. Yangon: FAME Publishing House; 2012. p. 36.

    Google Scholar 

  46. Line-Edwige M, Guy Raymond F, François E, Edouard N. Antiproliferative effect of alcoholic extracts of some Gabonese medicinal plants on human colonic cancer cells. Afr J Trad Compl Alt Med. 2010;6(2):112–7. https://doi.org/10.4314/ajtcam.v6i2.57081.

    Article  Google Scholar 

Download references

Acknowledgements

We wish to thank Ms. Su Su Saw and the staffs of FAME clinic for their help and cooperation.

Author information

Authors and Affiliations

  1. FAME Clinic, FAME Pharmaceuticals Industry Co., Ltd., Yangon, Myanmar

    Khin Maung Lwin

  2. Research and Development Department, FAME Pharmaceuticals Industry Co., Ltd., Yangon, Myanmar

    Yamin Kyaw Swar Dee & Ye Htut Linn

Authors
  1. Khin Maung Lwin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yamin Kyaw Swar Dee
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ye Htut Linn
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

KML treated the patient. YHL and YMKSD reviewed and wrote the manuscript. KML critically revised the manuscript.

Corresponding author

Correspondence to Ye Htut Linn.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Ethics Approval

The local IRBs have confirmed that no ethical approval is required for case reports. Consent to participate and consent for publication were taken from the patient. We declared that this manuscript/data has not been published or currently under review for publication elsewhere.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lwin, K.M., Dee, Y.K.S. & Linn, Y.H. The Effects of Supplement Therapy on HCV-Related HCC: a Case Report of a Patient Who Had Undergone TACE for Six Times. J Gastrointest Canc 52, 802–808 (2021). https://doi.org/10.1007/s12029-020-00540-7

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-020-00540-7

Search

Navigation